-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1698 Clinical Characteristics and Outcomes of Patients with Localized Stage High-Grade B-Cell Lymphoma (HGBCL) with or without MYC and BCL2 and/or BCL6 Rearrangements: A Retrospective Study from the Spanish Group Geltamo

Program: Oral and Poster Abstracts
Session: 626. Aggressive Lymphomas: Clinical and Epidemiological: Poster I
Hematology Disease Topics & Pathways:
Clinical Practice (Health Services and Quality)
Saturday, December 7, 2024, 5:30 PM-7:30 PM

Cristina García Herce1*, Anna Martín Carrizosa, MD1*, Lorenzo Carita2*, Víctor Navarro Garces2*, Belén Navarro3*, Eva Donato4*, Blanca Sánchez González5*, Clara González Santillana, MD6*, Ana Jiménez Ubieto7*, Luis Antonio López Gómez, MD8*, Angel Serna, MD1*, Ángeles Arnaldos López, MD9*, Ana Garcia Noblejas, MD, PhD10*, Concepción Nicolás11*, Rosalia Alonso Trillo, MD12*, Estefania Cerezo Velasco, MD13*, Daniel García Belmonte14*, Beatriz De La Cruz15*, Ana Alarcon Tomas, MD16*, Francesc Bosch, MD, PhD1 and Pau Abrisqueta, MD PhD1

1Hematology Department, Hospital Universitario Vall d’Hebron, Barcelona, Spain
2Statistic Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
3Hematology Department, Hospital Universitario Puerta de Hierro, Majadahonda, Spain
4Hematology Department, Hospital Universitario Doctor Peset, Valencia, Spain
5Hematology Department, Hospital del Mar, Barcelona, Spain
6Hematology Department, Hospital Universitario de Fuenlabrada, Madrid, Spain
7Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
8Hematology Department, Hospital Universitario Royo Villanova, Zaragoza, Spain
9Hematology Department, Hospital Universitario de Tarragona Juan XXIII, Tarragona, Spain
10Hematology Department, Hospital Universitario La Princesa, Madrid, Spain
11Hematology Department, Hospital Universitario Central de Asturias, Oviedo, Spain
12Hematology Department, Hospital Universitario de Getafe, Madrid, Spain
13Hematology Department, Consorcio Sanitario de Terrassa, Terrassa, Spain
14Hematology Department, Hospital Universitario la Zarzuela, Madrid, Spain
15Hematology Department, Hospital Universitario La Paz, Madrid, Spain
16Hematology Department, Hospital Universitario Puerta de Hierro, Majadahonda-Madrid, Spain

Background: HGBCL, with or without MYC, BCL2 and/or BCL6 rearrangements, constitute approximately 10-15% of diffuse large B-cell lymphomas (DLBCL). Most cases are diagnosed at advanced stages with associated poor prognosis and tend to be treated with high-dose chemoimmunotherapy. Nevertheless, there is limited data on the optimal treatment options for localized stages of this disease.

Methods: We conducted a retrospective, multicenter study in Spain, including patients diagnosed with double-hit (DH)/triple-hit (TH) HGBCL/DLBCL and HGBCL not otherwise specified (NOS), from January 2010 to May 2024. We analyzed demographic characteristics, treatment patterns (non-intensive vs. intensive treatments including dose-adjusted R-EPOCH, HyperCVAD, and BURKIMAB regimens), and survival outcomes according to clinical stage at diagnosis (localized vs. advanced stage). Kaplan-Meier and the COX model were used to analyze progression-free and overall survival (PFS and OS), as well as factors associated with these variables.

Results: A total of 156 patients from 14 GELTAMO centers were included in the study. Among them, 35 (22.3%) were diagnosed at Ann Arbor stage I-II. The median age at diagnosis was 71 years (IQR 63-76) for localized stages and 63 years (IQR 55-72) for advanced stages, with no sex differences observed. Patients with localized stages had better ECOG scores (89% at ECOG 0-1 vs. 71 %, p=0.062) and fewer patients with elevated LDH levels (53% vs. 81 %, p=0.002). Among advanced-stage patients, 31 (26%) had more than one extranodal site affected and 10 (8.4%) had central nervous system (CNS) involvement and 44 (36%) had bone marrow involvement at diagnosis. Four (11.4%) localized cases and 15 (12.3%) advanced cases were transformed from follicular lymphoma. According to the Hans algorithm, the germinal center cell type was present in 23 of 26 (88.4%) localized cases vs. 89 of 108 (82.4%) advanced cases, with no differences observed. Similarly, regarding rearrangements, there were no significant differences in the prevalence of DH and TH variants: DH-BCL2 was found in 31.4% of localized vs. 44.3% of advanced cases; DH-BCL6 in 14.2% vs. 17.2%; TH in 20% vs. 20.5%; and NOS in 34.3% vs. 18%.

Patterns of first-line treatment were similar between patients with localized or advanced disease: 10 (39%) patients with localized disease and 56 (48%) with advanced disease received intensive regimens, 16 (45.7%) and 50 (41%) receiving R-CHOP, while other treatments were administered to 8 (22.8%) and 16 (13.1%) of patients. The overall response rate was 60% in localized cases vs. 59% in advanced cases, while the complete response rate was 57% vs. 47.5%, respectively.

Overall, 53% of localized and 48% of advanced patients received one line of treatment, 28% vs. 20% received two lines, and 19% vs. 31% received three or more lines. CAR-T therapy was administered to 3.2% of localized and 21% of advanced patients, and bispecific antibodies to 11.4% vs. 8.2%. Autologous stem cell transplantation was performed in 6.5% vs. 10%, and allogeneic stem cell transplantation in 0% vs. 1.8%.

In the whole cohort, factors associated with PFS and OS included ECOG score, increased LDH, number of extranodal sites, and DH-BCL2/TH status (MYC-BCL2+/-BCL6 vs MYC-BCL6 or HGBCL-NOS). In the multivariable analysis, ECOG score and DH-BCL2/TH status retained their prognostic significance. Additionally, both univariable and multivariable analyses demonstrated that intensive treatment was associated with improved PFS.

With a median follow-up of 46 months (95% CI 40-71), no significant differences were observed in OS (p = 0.6) and PFS (p = 0.3) between localized and advanced stages. The 2-year PFS was 59% (44%–78%) for localized vs. 44% (36%–55%) for advanced stages, and 2-year OS was 58% (42%–79%) vs. 55% (46%–65%). There was 1 (2.8%) CNS relapse in the localized group compared to 6 (4.9%) in the advanced group.

Conclusion: In our series, patients with localized HGBCL had similar outcomes to those with advanced stages, suggesting that they should be treated with intensive regimens like those used for advanced disease.

Disclosures: García Herce: ABBVIE: Honoraria. Jiménez Ubieto: Novartis: Speakers Bureau; Lilly: Consultancy, Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Membership on an entity's Board of Directors or advisory committees; Janssen: Speakers Bureau; Roche: Consultancy, Speakers Bureau; Regeneron Pharmaceuticals, Inc.: Consultancy; Sandoz: Speakers Bureau; Incyte: Speakers Bureau; Kite-Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Genmab: Consultancy, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Serna: Astrazeneca: Honoraria; Roche: Honoraria; Incyte: Honoraria; Janssen: Honoraria; AbbVie: Honoraria. Arnaldos López: Janssen: Honoraria. Bosch: Enterome: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: payment for expert testimony; Lava Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: payment for expert testimony; Advantage Allogene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: payment for expert testimony; TG Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: payment for expert testimony; Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: payment for expert testimony; BeiGene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: payment for expert testimony; Lilly: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: payment for expert testimony; AstraZeneca: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: payment for expert testimony; Celgene/BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: payment for expert testimony; Mundipharma: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: payment for expert testimony; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: payment for expert testimony; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: payment for expert testimony; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: payment for expert testimony; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: payment for expert testimony; Genentech: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: payment for expert testimony; AbbVie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: payment for expert testimony. Abrisqueta: Astrazeneca: Consultancy, Honoraria, Speakers Bureau; Janssen: Consultancy, Honoraria, Speakers Bureau; Abbvie: Consultancy, Honoraria, Speakers Bureau; Roche: Consultancy, Honoraria, Speakers Bureau; Beigene: Consultancy; BMS: Consultancy, Honoraria, Speakers Bureau; Incyte: Honoraria, Speakers Bureau.

*signifies non-member of ASH